



Supplemental Figure 1: Long-term IL-17 treatment promotes *in vitro* conversion of human hepatic progenitor cell line HepaRG into CSC phenotype by undergoing their **A)** dedifferentiation through reducing expression of the hepatocyte markers Albumin and HNF4 α and **B)** acquisition of stem cell markers CD133 and EpCAM



Supplemental Figure 2: Validation of miR-122 expression after LPC transfection with miR-122 mimics



Supplemental Figure 3 : Stable-IL-17 transfection in LPC leads to their *in vitro* transformation into CSC phenotype thus rendering these transfected cells suitable for *in vivo* subcutaneous tumor generation. **A)** qPCR analyses showing induction of stem cell CD133 and tumor Glypican 3 expression. **B)** Flow cytometric analysis revealing induction of CD133⁺ cells in LPC population and **C)** IL-17 production in transfected cell culture supernatant

